3651 - 3660 of 9145 Results
Title
Year
-
OPENTitle: Nicotine‐Mediated Rescue of α‐Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in DrosophilaJournal Name: Movement DisordersPublisher: WileyVol: 38Issue #: 2Start Page: 244End Page: 255Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.29283Best OA location URL: https://doi.org/10.1002/mds.29283Citation Count: 33
-
OPENTitle: Extracellular Vesicle‐Mediated Delivery of Constrained Peptides Disrupts the Pathogenic Interaction of LRRK2‐FADD in Parkinson's DiseaseJournal Name: Journal of Extracellular BiologyPublisher: WileyVol: 5Issue #: 2Start Page: e70116End Page: e70116Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/jex2.70116Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jex2.70116Citation Count: 2
-
OPENTitle: Phenotypical variability in the 6-OHDA mouse model of Parkinson's disease despite consistent and robust nigral lesioningJournal Name: Brain MechanismsPublisher: Elsevier BVVol: 148-150Issue #:Start Page: 202523End Page: 202523Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.bramec.2025.202523Best OA location URL: https://doi.org/10.1016/j.bramec.2025.202523Citation Count: 1
- Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study2018RESTRICTEDTitle: Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 18Issue #: 2Start Page: 165End Page: 176Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(18)30391-0Citation Count: 109
- Characterization of a Parkinson’s disease rat model using an upgraded paraquat exposure paradigm2020RESTRICTEDTitle: Characterization of a Parkinson’s disease rat model using an upgraded paraquat exposure paradigmJournal Name: European Journal of NeurosciencePublisher: WileyVol: 52Issue #: 4Start Page: 3242End Page: 3255Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/ejn.14683Citation Count: 33
-
RESTRICTEDTitle: Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathologyJournal Name: Acta NeuropathologicaPublisher: Springer Science and Business Media LLCVol: 131Issue #: 3Start Page: 393End Page: 409Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s00401-015-1526-9Best OA location URL: http://doi.org/10.1007/s00401-015-1526-9Citation Count: 183
- Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains2010RESTRICTEDTitle: Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brainsJournal Name: Movement DisordersPublisher: WileyVol: 26Issue #: 1Start Page: 27End Page: 36Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.23442Citation Count: 169
- α4β2 * Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait–Balance Disorders2021OPENTitle: α4β2 * Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait–Balance DisordersJournal Name: Annals of NeurologyPublisher: WileyVol: 90Issue #: 1Start Page: 130End Page: 142Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/ana.26102Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ana.26102Citation Count: 25
-
OPENTitle: Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker‐Defined SynucleinopathyJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/acn3.70399Best OA location URL: https://doi.org/10.1002/acn3.70399Citation Count: 1
-
OPENTitle: l‐3,4‐dihydroxyphenylalanine (l‐DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha‐synuclein mouse models of Parkinson's diseaseJournal Name: Journal of NeurochemistryPublisher: WileyVol: 150Issue #: 1Start Page: 88End Page: 106Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1111/jnc.14676Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jnc.14676Citation Count: 37